NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 40.48 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $2.391 million which missed the analyst consensus estimate of $2.576 million by 7.19 percent. This is a 72.44 percent increase over sales of $1.387 million the same period last year.